DE69916807D1 - Kostimulatorische blockade und gemischter chimerismus in allotransplantationen - Google Patents

Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Info

Publication number
DE69916807D1
DE69916807D1 DE69916807T DE69916807T DE69916807D1 DE 69916807 D1 DE69916807 D1 DE 69916807D1 DE 69916807 T DE69916807 T DE 69916807T DE 69916807 T DE69916807 T DE 69916807T DE 69916807 D1 DE69916807 D1 DE 69916807D1
Authority
DE
Germany
Prior art keywords
allotransplantations
mixed chimerism
costimulatory blockade
blockade
costimulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69916807T
Other languages
English (en)
Other versions
DE69916807T2 (de
Inventor
Megan Sykes
H Sayegh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
General Hospital Corp
Original Assignee
Brigham and Womens Hospital Inc
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc, General Hospital Corp filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of DE69916807D1 publication Critical patent/DE69916807D1/de
Publication of DE69916807T2 publication Critical patent/DE69916807T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Artificial Fish Reefs (AREA)
DE1999616807 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen Expired - Fee Related DE69916807T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7386498P 1998-02-04 1998-02-04
US73864P 1998-02-04
PCT/US1999/002542 WO1999039727A1 (en) 1998-02-04 1999-02-04 Costimulatory blockade and mixed chimerism in allotransplantation

Publications (2)

Publication Number Publication Date
DE69916807D1 true DE69916807D1 (de) 2004-06-03
DE69916807T2 DE69916807T2 (de) 2005-01-13

Family

ID=22116269

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999616807 Expired - Fee Related DE69916807T2 (de) 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Country Status (9)

Country Link
US (3) US6280957B1 (de)
EP (2) EP1058555B1 (de)
JP (2) JP2002502824A (de)
AT (1) ATE265220T1 (de)
AU (2) AU748443B2 (de)
CA (2) CA2319764A1 (de)
DE (1) DE69916807T2 (de)
IL (2) IL137614A0 (de)
WO (2) WO1999039726A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201977T3 (es) * 1996-05-09 2004-04-01 The General Hospital Corporation Quimerismo mixto y tolerancia.
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CN1360596A (zh) * 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
ATE311199T1 (de) * 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
WO2001000679A2 (en) * 1999-06-29 2001-01-04 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU778929B2 (en) * 1999-12-06 2004-12-23 General Hospital Corporation, The Pancreatic stem cells and their use in transplantation
AU2001247401A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
KR20040023565A (ko) * 2000-09-18 2004-03-18 아이덱 파마슈티칼즈 코포레이션 Ｂ 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
EP1368059A1 (de) * 2001-01-26 2003-12-10 Emory University Methoden zur induktion der organstransplantat-toleranz und zur korrektur von hämoglobinopathien
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
PT1391464E (pt) 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
EP1549277A4 (de) * 2002-05-22 2007-09-05 Cleveland Clinic Foundation Einleitung und aufrechterhaltung von toleranz gegenüber zusammengesetzten gewebe-allotransplantaten
CA2535583A1 (en) * 2003-08-25 2005-03-03 Pangenetics B.V. Method of inducing immune tolerance
US20050112122A1 (en) * 2003-09-02 2005-05-26 Greiner Dale L. Generation of hematopoietic chimerism and induction of central tolerance
WO2005110481A2 (en) 2004-05-14 2005-11-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US20070113297A1 (en) * 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
RU2445975C2 (ru) 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
US9527912B2 (en) * 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
DK2683406T3 (da) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anti-cd40-antistoffer og anvendelser deraf
GB2558680B (en) 2013-02-26 2018-10-03 Univ Leland Stanford Junior Combined organ and hematopoietic cells for transplantation tolerance of grafts
EP3033093A1 (de) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Behandlung von transplantatabstossung durch verabreichung eines komplementinhibitors an ein organ vor der transplantation
CN107249318A (zh) 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
JP6976931B2 (ja) 2015-09-04 2021-12-08 プリマトープ・セラピューティクス・インコーポレイテッド ヒト化抗ｃｄ４０抗体及びその使用
EP3765044A4 (de) 2018-03-12 2021-12-08 Medeor Therapeutics, Inc. Verfahren zur behandlung von nichtkanzerösen erkrankungen unter verwendung von hämatopoetischen zellen
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
ES2172514T3 (es) 1992-01-08 2002-10-01 Gen Hospital Corp Tolerancia inducida a los xenoinjertos.
WO1994026289A1 (en) 1992-02-19 1994-11-24 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
JPH10501815A (ja) * 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
IL125928A (en) 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
ES2201977T3 (es) 1996-05-09 2004-04-01 The General Hospital Corporation Quimerismo mixto y tolerancia.
CA2260752A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways

Also Published As

Publication number Publication date
IL137361A0 (en) 2001-07-24
WO1999039726A1 (en) 1999-08-12
CA2319764A1 (en) 1999-08-12
DE69916807T2 (de) 2005-01-13
US6280957B1 (en) 2001-08-28
ATE265220T1 (de) 2004-05-15
IL137614A0 (en) 2001-07-24
WO1999039727A1 (en) 1999-08-12
EP1053006A4 (de) 2002-09-25
AU2583999A (en) 1999-08-23
US6514513B1 (en) 2003-02-04
EP1058555A1 (de) 2000-12-13
AU2588099A (en) 1999-08-23
US20020055122A1 (en) 2002-05-09
EP1058555A4 (de) 2001-02-28
AU748443B2 (en) 2002-06-06
CA2319448A1 (en) 1999-08-12
JP2002502824A (ja) 2002-01-29
EP1053006A1 (de) 2000-11-22
EP1058555B1 (de) 2004-04-28
JP2002502823A (ja) 2002-01-29
AU746825B2 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
DE69916807D1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
ES2195664T3 (es) Uso de fumaratos de dialquilo.
ES2194106T3 (es) .ompuestos de imidazol
TR200103216T2 (tr) Pirimidinon bileşimleri
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
ATE233735T1 (de) Neue phenanthridine
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
ATE255632T1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
NO20031860D0 (no) Kahalaolid F
DE69731400D1 (de) Proliferation humaner endokriner pankreaszellen in kultur
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
FR2749022B1 (fr) Cellules aviaires immortelles
IS4915A (is) Samsetningar sem innihalda VX478, Zídóvúdín, FTC og/eða 3TC til að nota við meðhöndlunina á HIV
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
ES2144626T3 (es) Uso de peptidos de adhesion celular para la modificacion del poder de adhesion de celulas eucarioticas entre si.
HUP0101393A1 (hu) Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK0949221T3 (da) Sammensætning, som er egnet som flydende gödning og som indeholder svovl i form af kaliumtetrathionat
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
ATE221388T1 (de) Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DER ZWEITE ANMELDER LAUTET RICHTIG: THE BRIGHAM & WOMEN'S HOSPITAL, BOSTON

8339 Ceased/non-payment of the annual fee